Harvey Investment Co. LLC cut its stake in shares of AbbVie Inc (NYSE:ABBV) by 2.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 110,938 shares of the company’s stock after selling 2,600 shares during the quarter. AbbVie makes up about 1.9% of Harvey Investment Co. LLC’s portfolio, making the stock its 21st largest position. Harvey Investment Co. LLC’s holdings in AbbVie were worth $9,858,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of AbbVie by 3.3% in the second quarter. Vanguard Group Inc. now owns 115,920,673 shares of the company’s stock valued at $8,405,409,000 after purchasing an additional 3,706,941 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of AbbVie by 1,949.7% in the second quarter. Janus Henderson Group PLC now owns 3,833,535 shares of the company’s stock valued at $277,967,000 after purchasing an additional 3,646,510 shares during the last quarter. Orbis Allan Gray Ltd raised its holdings in shares of AbbVie by 35.7% in the second quarter. Orbis Allan Gray Ltd now owns 12,704,919 shares of the company’s stock valued at $921,233,000 after purchasing an additional 3,340,038 shares during the last quarter. Capital Research Global Investors raised its holdings in shares of AbbVie by 1.2% in the second quarter. Capital Research Global Investors now owns 178,274,835 shares of the company’s stock valued at $12,926,708,000 after purchasing an additional 2,130,919 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in shares of AbbVie by 2.0% in the second quarter. BlackRock Inc. now owns 94,074,962 shares of the company’s stock valued at $6,821,375,000 after purchasing an additional 1,864,418 shares during the last quarter. 69.18% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts recently issued reports on the stock. BMO Capital Markets set a $84.00 price objective on shares of AbbVie and gave the stock a “hold” rating in a report on Thursday. Vetr downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating and set a $113.08 price objective for the company. in a report on Monday. Barclays reiterated a “hold” rating and set a $68.00 target price on shares of AbbVie in a research report on Thursday, September 28th. Piper Jaffray Companies reiterated a “buy” rating on shares of AbbVie in a research report on Tuesday, January 2nd. Finally, Evercore ISI reiterated an “outperform” rating and set a $100.00 target price (up previously from $95.00) on shares of AbbVie in a research report on Saturday, September 30th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. AbbVie currently has a consensus rating of “Buy” and a consensus target price of $100.94.
In other news, Chairman Richard A. Gonzalez sold 218,193 shares of the business’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total transaction of $20,512,323.93. Following the sale, the chairman now owns 492,030 shares in the company, valued at approximately $46,255,740.30. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Timothy J. Richmond sold 87,040 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the sale, the senior vice president now owns 113,118 shares in the company, valued at approximately $11,136,467.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 494,676 shares of company stock worth $47,237,938. 0.23% of the stock is currently owned by company insiders.
Shares of AbbVie Inc (NYSE:ABBV) traded down $0.42 during trading on Thursday, reaching $99.27. 4,240,900 shares of the company’s stock traded hands, compared to its average volume of 4,480,000. The company has a market capitalization of $158,250.00, a price-to-earnings ratio of 24.09, a PEG ratio of 1.20 and a beta of 1.53. AbbVie Inc has a twelve month low of $59.27 and a twelve month high of $101.28. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08.
AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.39 by $0.02. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The firm had revenue of $7 billion for the quarter, compared to the consensus estimate of $7 billion. During the same period last year, the firm posted $1.21 earnings per share. The business’s revenue was up 8.8% compared to the same quarter last year. analysts anticipate that AbbVie Inc will post 5.55 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be issued a $0.71 dividend. The ex-dividend date is Thursday, January 11th. This represents a $2.84 annualized dividend and a yield of 2.86%. This is a boost from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s payout ratio is 62.14%.
WARNING: “Harvey Investment Co. LLC Trims Stake in AbbVie Inc (NYSE:ABBV)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/11/harvey-investment-co-llc-sells-2600-shares-of-abbvie-inc-abbv.html.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.